Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-312024-12-31true772024-01-01falseproviding sales and marketing activity for its parent company.falsefalse 11457556 2024-01-01 2024-12-31 11457556 2023-01-01 2023-12-31 11457556 2024-12-31 11457556 2023-12-31 11457556 2023-01-01 11457556 c:Director2 2024-01-01 2024-12-31 11457556 d:CurrentFinancialInstruments 2024-12-31 11457556 d:CurrentFinancialInstruments 2023-12-31 11457556 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 11457556 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 11457556 d:ShareCapital 2024-01-01 2024-12-31 11457556 d:ShareCapital 2024-12-31 11457556 d:ShareCapital 2023-01-01 2023-12-31 11457556 d:ShareCapital 2023-12-31 11457556 d:ShareCapital 2023-01-01 11457556 d:RetainedEarningsAccumulatedLosses 2024-01-01 2024-12-31 11457556 d:RetainedEarningsAccumulatedLosses 2024-12-31 11457556 d:RetainedEarningsAccumulatedLosses 2023-01-01 2023-12-31 11457556 d:RetainedEarningsAccumulatedLosses 2023-12-31 11457556 d:RetainedEarningsAccumulatedLosses 2023-01-01 11457556 c:FRS102 2024-01-01 2024-12-31 11457556 c:Audited 2024-01-01 2024-12-31 11457556 c:FullAccounts 2024-01-01 2024-12-31 11457556 c:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 11457556 d:WithinOneYear 2024-12-31 11457556 d:WithinOneYear 2023-12-31 11457556 d:BetweenOneFiveYears 2024-12-31 11457556 d:BetweenOneFiveYears 2023-12-31 11457556 c:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 11457556 2 2024-01-01 2024-12-31 11457556 e:PoundSterling 2024-01-01 2024-12-31 iso4217:GBP xbrli:pure

Registered number: 11457556









IMMEDICA PHARMA UK LIMITED









FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2024

 
IMMEDICA PHARMA UK LIMITED
REGISTERED NUMBER: 11457556

BALANCE SHEET
AS AT 31 DECEMBER 2024

2024
2023
Note
£
£

  

Current assets
  

Debtors: amounts falling due within one year
 5 
460,355
181,230

Cash at bank and in hand
 6 
67,447
184,809

  
527,802
366,039

Creditors: amounts falling due within one year
 7 
(287,353)
(238,510)

Net current assets
  
 
 
240,449
 
 
127,529

Total assets less current liabilities
  
240,449
127,529

  

Net assets
  
240,449
127,529


Capital and reserves
  

Called up share capital 
  
100
100

Profit and loss account
  
240,349
127,429

  
240,449
127,529


The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 



................................................
P A Edvell
Director

Date: 4 August 2025

The notes on pages 3 to 7 form part of these financial statements.
Page 1

 
IMMEDICA PHARMA UK LIMITED
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024


Called up share capital
Profit and loss account
Total equity

£
£
£


At 1 January 2023
100
213,124
213,224


Comprehensive income for the year

Profit for the year
-
54,305
54,305
Total comprehensive income for the year
-
54,305
54,305


Contributions by and distributions to owners

Dividends - See Note 4
-
(140,000)
(140,000)


Total transactions with owners
-
(140,000)
(140,000)



At 1 January 2024
100
127,429
127,529


Comprehensive income for the year

Profit for the year
-
112,920
112,920
Total comprehensive income for the year
-
112,920
112,920


Total transactions with owners
-
-
-


At 31 December 2024
100
240,349
240,449


The notes on pages 3 to 7 form part of these financial statements.
Page 2

 
IMMEDICA PHARMA UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1.


General information

Immedica Pharma UK Limited ("The Company") is a company incorporated in the United Kingdom under the Companies Act. The Company is a private company, limited by shares and is registered in England & Wales. The registered office Suite 4, 7th Floor 50 Broadway, London SW1H 0DB.
 
The Company was incorporated on 10 July 2018 as Medical Need UK Limited. On 13 June 2019, the Company changed its name to Immedica Pharma UK Limited. 
The principal activity of the company in the period under review was that of providing sales and marketing services for its parent company.
The Company's functional and presentational currency is GBP. Balances are rounded to the nearest whole £.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

The following principal accounting policies have been applied:

 
2.2

Going concern

The Company has obtained a letter of support from its parent, Immedica Pharma AB. The directors of Immedica Pharma AB have provided a commitment to provide any financial support which may be necessary in order that the Company can continue to meet its liabilities, as they fall due, for the foreseeable future. 
As a result of this commitment the directors have continued to adopt the going concern basis in preparing these financial statements.

 
2.3

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Turnover represents amounts charged to the parent company under a services and marketing agreement, excluding value added taxation. Turnover is recognised when costs are incurred. 

Page 3

 
IMMEDICA PHARMA UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.4

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

 
2.5

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.6

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

 
2.7

Share based payment schemes

Where share related schemes provide awards to employees, an appropriate expense, based on determined fair values, is charged to the profit and loss account, subject to certain criteria being met. These are either factors beyond the control of either party (such as a target based on an index) or factors which are within the control of one or other of the parties (such as the Company keeping the scheme open or the employee maintaining any contributions required by the scheme).

Page 4

 
IMMEDICA PHARMA UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.8

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


 
2.9

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.10

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.11

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.12

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

Page 5

 
IMMEDICA PHARMA UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

3.


Employees

The average monthly number of employees, including directors, during the year was 7 (2023 - 7).


4.


Dividends

2024
2023
£
£


Dividends
-
140,000

On 30 March 2023 a dividend of £140,000 was proposed and paid.


5.


Debtors

2024
2023
£
£


Amounts owed by group undertakings
414,210
125,947

Other debtors
20,783
29,222

Prepayments and accrued income
25,362
20,219

Deferred taxation
-
5,842

460,355
181,230



6.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
67,447
184,809



7.


Creditors: Amounts falling due within one year

2024
2023
£
£

Trade creditors
3,513
2,852

Corporation tax
35,140
20,880

Other taxation and social security
31,129
11,541

Accruals and deferred income
217,571
203,237

287,353
238,510


Page 6

 
IMMEDICA PHARMA UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

8.


Pension commitments

The Company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Company  in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £71,066 (2023- £59,557) contributions totalling were £31,129 (2023 - £11,541) payable to the fund at the balance sheet date and are included in creditors.


9.


Commitments under operating leases

At 31 December 2024 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

2024
2023
£
£


Not later than 1 year
34,988
34,988

Later than 1 year and not later than 5 years
73,548
74,011

108,536
108,999


10.


Controlling party

The immediate parent company is Immedica Pharma AB, a company incorporated in Sweden. Immedica Pharma Holding AB, the immedicate parent company of Immedica Pharma AB, is the smallest entity to include Immedica Pharma UK Ltd in its consolidated financial statements. The principal place of business of Immedica Pharma AB is Solnavägen 3H, 113 36 Stockholm, Sweden.
Until 19 September 2024 the ultimate controlling party is Impilo Holdings AB. On 19 September 2024 the ultimate controlling party became Immedica Topco AB. Immedica Topco AB is the largest company to include Immedica Pharma UK Limited in its consolidated accounts.


11.


Auditor's information

The auditor's report on the financial statements for the year ended 31 December 2024 was unqualified.

The audit report was signed on 4 August 2025 by Simon Buss (Senior Statutory Auditor) on behalf of Nortons Assurance Limited.

 
Page 7